Zevalin Causes Long-Lasting Remissions, Researchers Say
Luke Timmerman12/8/08
Follow-up data from a trial of 409 patients with non-Hodgkin’s lymphoma shows that treatment with Zevalin is long lasting, said the drug’s marketer, Seattle-based Cell Therapeutics (NASDAQ: CTIC). Researchers found that patients who had their tumors completely wiped out after taking Zevalin remained in remission for at least 67 months, compared with 31 months for patients in a control group, the company said today in a statement at the American Society of Hematology meeting in San Francisco. Cell Therapeutics recently signed a partnership with Spectrum Pharmaceuticals to co-market the drug, and is seeking permission from the FDA to sell it to a broader group of lymphoma patients.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
